Share Price and Basic Stock Data
Last Updated: February 7, 2026, 7:27 pm
| PEG Ratio | 1.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jagsonpal Pharmaceuticals Ltd operates within the pharmaceuticals sector, demonstrating a solid revenue performance with reported sales of ₹283 Cr for the trailing twelve months (TTM). The revenue trajectory has shown resilience, growing from ₹218 Cr in FY 2022 to ₹269 Cr in FY 2025. The quarterly sales figures indicate fluctuations, with a peak of ₹75 Cr in September 2024, followed by a decline to ₹59 Cr in March 2025. This volatility may reflect seasonal trends or market dynamics impacting demand. Notably, the operating profit margin (OPM) has improved significantly, standing at 20.60% in FY 2025 compared to 12.88% in FY 2022, indicating enhanced operational efficiency. The company’s ability to generate strong revenues despite market challenges underscores its competitive positioning within the sector.
Profitability and Efficiency Metrics
Jagsonpal Pharmaceuticals has reported a net profit of ₹62 Cr for FY 2025, a substantial increase from ₹19 Cr in FY 2022. The company’s return on equity (ROE) stood at 18.6%, reflecting effective utilization of shareholders’ funds to generate profits. The interest coverage ratio (ICR) is notably high at 61.86x, indicating that the company comfortably meets its interest obligations with earnings. The cash conversion cycle (CCC) of 39 days showcases efficient management of working capital, positioning the company favorably compared to industry norms, which often exceed 60 days. However, the operating profit figures displayed inconsistency, with a drop to ₹3 Cr in December 2023, suggesting potential challenges in maintaining cost control during certain periods. Overall, the profitability metrics highlight a robust financial performance, although the volatility in operating profits warrants close monitoring.
Balance Sheet Strength and Financial Ratios
Jagsonpal Pharmaceuticals boasts a strong balance sheet, with a market capitalization of ₹1,123 Cr and net assets amounting to ₹299 Cr as of September 2025. The company has minimal borrowings of ₹9 Cr, resulting in a debt-to-equity ratio of 0.00, reflecting a conservative capital structure that supports financial stability. Reserves have increased to ₹240 Cr, providing a cushion for future investments and growth initiatives. The price-to-book value (P/BV) stands at 5.99x, which, while higher than typical sector averages, indicates investor confidence in the company’s growth prospects. Additionally, the return on capital employed (ROCE) of 23% signifies effective asset utilization, enhancing shareholder value. However, the elevated P/BV may raise concerns regarding valuation sustainability, particularly if future earnings growth does not meet market expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Jagsonpal Pharmaceuticals reveals a strong promoter holding of 67.54%, which is indicative of management’s commitment and confidence in the company’s strategy. Foreign institutional investors (FIIs) have gradually increased their stake to 2.12%, while domestic institutional investors (DIIs) remain minimal at 0.08%. The number of shareholders has grown significantly to 24,653 by September 2025, reflecting increasing retail investor interest. This heightened participation can be attributed to the company’s strong financial performance and growth trajectory. However, the declining trend in promoter shareholding from 68.72% in December 2022 to the current level may raise concerns about potential dilution of control. Overall, the shareholding dynamics suggest a stable base of support but warrant scrutiny regarding long-term governance implications.
Outlook, Risks, and Final Insight
Looking ahead, Jagsonpal Pharmaceuticals is well-positioned for growth, bolstered by its strong financial metrics and operational efficiencies. However, the company faces risks including market volatility, which could impact sales and profitability, especially given the recent fluctuations in quarterly revenues. Additionally, the pharmaceutical sector is subject to regulatory changes that could influence operational costs and market access. The high P/BV ratio suggests that the market has high expectations for future growth, which the company needs to meet to maintain investor confidence. Should Jagsonpal successfully navigate these challenges and continue to enhance its operational efficiencies, it could solidify its market position and drive sustainable growth. Conversely, failure to manage costs or adapt to market changes could put pressure on margins and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 185/84.3 | 28.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,529 Cr. | 324 | 479/192 | 73.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,604.55 Cr | 1,093.01 | 42.93 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 55 | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 |
| Expenses | 52 | 50 | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 |
| Operating Profit | 9 | 5 | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 |
| OPM % | 14% | 10% | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% | 22% |
| Other Income | 2 | 3 | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 7 | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 |
| Tax % | 21% | 24% | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% | 25% |
| Net Profit | 8 | 6 | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 |
| EPS in Rs | 1.19 | 0.85 | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 |
Last Updated: February 5, 2026, 11:09 am
Below is a detailed analysis of the quarterly data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 73.00 Cr.. The value appears to be declining and may need further review. It has decreased from 74.00 Cr. (Sep 2025) to 73.00 Cr., marking a decrease of 1.00 Cr..
- For Expenses, as of Dec 2025, the value is 57.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 58.00 Cr. (Sep 2025) to 57.00 Cr., marking a decrease of 1.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 16.00 Cr..
- For OPM %, as of Dec 2025, the value is 22.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 22.00%.
- For Other Income, as of Dec 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Sep 2025) to 1.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Sep 2025) to 15.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Dec 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 25.00%.
- For Net Profit, as of Dec 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Sep 2025) to 11.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 1.64. The value appears to be declining and may need further review. It has decreased from 1.89 (Sep 2025) to 1.64, marking a decrease of 0.25.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 283 |
| Expenses | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 227 |
| Operating Profit | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 55 |
| OPM % | 7% | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% |
| Other Income | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 34 |
| Interest | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit before tax | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 79 |
| Tax % | 16% | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | |
| Net Profit | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 62 |
| EPS in Rs | 0.32 | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 9.32 |
| Dividend Payout % | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 300.00% | -200.00% | 158.33% | 14.29% | 112.50% | 11.76% | 42.11% | -18.52% | 150.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | 100.00% | -500.00% | 358.33% | -144.05% | 98.21% | -100.74% | 30.34% | -60.62% | 168.52% |
Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 38% |
| 3 Years: | 29% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 75% |
| 3 Years: | 16% |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:00 am
Balance Sheet
Last Updated: December 10, 2025, 2:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 240 |
| Borrowings | 36 | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 9 |
| Other Liabilities | 22 | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 37 |
| Total Liabilities | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
| Fixed Assets | 56 | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 90 |
| CWIP | 2 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
| Other Assets | 98 | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 209 |
| Total Assets | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
Below is a detailed analysis of the balance sheet data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 13.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 37.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 299.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 90.00 Cr.. The value appears to be declining and may need further review. It has decreased from 94.00 Cr. (Mar 2025) to 90.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 184.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Sep 2025, the value is 299.00 Cr.. The value appears strong and on an upward trend. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
Notably, the Reserves (240.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -30.00 | -26.00 | -2.00 | -19.00 | 5.00 | 4.00 | 12.00 | 26.00 | 28.00 | 14.00 | 42.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 |
| Inventory Days | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 |
| Days Payable | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 |
| Cash Conversion Cycle | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 |
| Working Capital Days | 64 | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 |
| ROCE % | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 83 | 0.04 | 0 | 83 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.26 | 8.49 | 10.20 | 7.48 | 6.51 |
| Diluted EPS (Rs.) | 8.22 | 8.46 | 10.20 | 7.48 | 6.51 |
| Cash EPS (Rs.) | 9.56 | 9.13 | 10.66 | 8.06 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 46.96 | 43.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 49.95 | 46.54 |
| Dividend / Share (Rs.) | 2.50 | 5.00 | 5.00 | 4.00 | 1.00 |
| Revenue From Operations / Share (Rs.) | 40.47 | 78.94 | 90.36 | 86.30 | 71.74 |
| PBDIT / Share (Rs.) | 8.92 | 12.23 | 15.22 | 11.12 | 8.96 |
| PBIT / Share (Rs.) | 7.70 | 11.61 | 14.76 | 10.54 | 8.76 |
| PBT / Share (Rs.) | 10.52 | 11.30 | 13.29 | 10.43 | 8.35 |
| Net Profit / Share (Rs.) | 8.34 | 8.50 | 10.20 | 7.48 | 6.51 |
| PBDIT Margin (%) | 22.05 | 15.49 | 16.84 | 12.88 | 12.48 |
| PBIT Margin (%) | 19.02 | 14.70 | 16.34 | 12.20 | 12.21 |
| PBT Margin (%) | 25.99 | 14.31 | 14.70 | 12.08 | 11.63 |
| Net Profit Margin (%) | 20.60 | 10.76 | 11.28 | 8.66 | 9.07 |
| Return on Networth / Equity (%) | 23.11 | 11.98 | 16.81 | 15.92 | 14.95 |
| Return on Capital Employeed (%) | 20.26 | 15.50 | 23.10 | 20.55 | 18.54 |
| Return On Assets (%) | 19.89 | 10.34 | 13.70 | 11.62 | 10.38 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Asset Turnover Ratio (%) | 1.08 | 1.01 | 1.30 | 1.36 | 1.21 |
| Current Ratio (X) | 6.22 | 10.42 | 5.97 | 3.24 | 2.98 |
| Quick Ratio (X) | 5.64 | 9.63 | 5.22 | 2.37 | 2.25 |
| Inventory Turnover Ratio (X) | 17.80 | 1.24 | 1.24 | 1.36 | 1.31 |
| Dividend Payout Ratio (NP) (%) | 23.89 | 58.31 | 0.00 | 53.50 | 15.35 |
| Dividend Payout Ratio (CP) (%) | 20.83 | 54.29 | 0.00 | 49.63 | 14.91 |
| Earning Retention Ratio (%) | 76.11 | 41.69 | 0.00 | 46.50 | 84.65 |
| Cash Earning Retention Ratio (%) | 79.17 | 45.71 | 0.00 | 50.37 | 85.09 |
| Interest Coverage Ratio (X) | 61.86 | 39.74 | 96.57 | 102.18 | 21.61 |
| Interest Coverage Ratio (Post Tax) (X) | 38.24 | 28.60 | 74.08 | 69.70 | 16.71 |
| Enterprise Value (Cr.) | 1305.18 | 591.93 | 644.85 | 795.42 | 154.96 |
| EV / Net Operating Revenue (X) | 4.86 | 2.84 | 2.72 | 3.52 | 0.82 |
| EV / EBITDA (X) | 22.02 | 18.30 | 16.17 | 27.31 | 6.60 |
| MarketCap / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| Retention Ratios (%) | 76.10 | 41.68 | 0.00 | 46.49 | 84.64 |
| Price / BV (X) | 5.99 | 3.95 | 4.78 | 6.68 | 1.83 |
| Price / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.02 | 0.08 |
After reviewing the key financial ratios for Jagsonpal Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.00, marking a decrease of 3.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.26. This value is within the healthy range. It has decreased from 8.49 (Mar 24) to 8.26, marking a decrease of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.22. This value is within the healthy range. It has decreased from 8.46 (Mar 24) to 8.22, marking a decrease of 0.24.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.56. This value is within the healthy range. It has increased from 9.13 (Mar 24) to 9.56, marking an increase of 0.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Dividend / Share (Rs.), as of Mar 25, the value is 2.50. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.50, marking a decrease of 2.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 40.47. It has decreased from 78.94 (Mar 24) to 40.47, marking a decrease of 38.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.92. This value is within the healthy range. It has decreased from 12.23 (Mar 24) to 8.92, marking a decrease of 3.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. It has decreased from 11.61 (Mar 24) to 7.70, marking a decrease of 3.91.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.30 (Mar 24) to 10.52, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.34. This value is within the healthy range. It has decreased from 8.50 (Mar 24) to 8.34, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 15.49 (Mar 24) to 22.05, marking an increase of 6.56.
- For PBIT Margin (%), as of Mar 25, the value is 19.02. This value is within the healthy range. It has increased from 14.70 (Mar 24) to 19.02, marking an increase of 4.32.
- For PBT Margin (%), as of Mar 25, the value is 25.99. This value is within the healthy range. It has increased from 14.31 (Mar 24) to 25.99, marking an increase of 11.68.
- For Net Profit Margin (%), as of Mar 25, the value is 20.60. This value exceeds the healthy maximum of 10. It has increased from 10.76 (Mar 24) to 20.60, marking an increase of 9.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 23.11. This value is within the healthy range. It has increased from 11.98 (Mar 24) to 23.11, marking an increase of 11.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.26. This value is within the healthy range. It has increased from 15.50 (Mar 24) to 20.26, marking an increase of 4.76.
- For Return On Assets (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 19.89, marking an increase of 9.55.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.08. It has increased from 1.01 (Mar 24) to 1.08, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 6.22. This value exceeds the healthy maximum of 3. It has decreased from 10.42 (Mar 24) to 6.22, marking a decrease of 4.20.
- For Quick Ratio (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 2. It has decreased from 9.63 (Mar 24) to 5.64, marking a decrease of 3.99.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 17.80. This value exceeds the healthy maximum of 8. It has increased from 1.24 (Mar 24) to 17.80, marking an increase of 16.56.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 58.31 (Mar 24) to 23.89, marking a decrease of 34.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.83. This value is within the healthy range. It has decreased from 54.29 (Mar 24) to 20.83, marking a decrease of 33.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.11. This value exceeds the healthy maximum of 70. It has increased from 41.69 (Mar 24) to 76.11, marking an increase of 34.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.17. This value exceeds the healthy maximum of 70. It has increased from 45.71 (Mar 24) to 79.17, marking an increase of 33.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 61.86. This value is within the healthy range. It has increased from 39.74 (Mar 24) to 61.86, marking an increase of 22.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.24. This value is within the healthy range. It has increased from 28.60 (Mar 24) to 38.24, marking an increase of 9.64.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,305.18. It has increased from 591.93 (Mar 24) to 1,305.18, marking an increase of 713.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.86. This value exceeds the healthy maximum of 3. It has increased from 2.84 (Mar 24) to 4.86, marking an increase of 2.02.
- For EV / EBITDA (X), as of Mar 25, the value is 22.02. This value exceeds the healthy maximum of 15. It has increased from 18.30 (Mar 24) to 22.02, marking an increase of 3.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For Retention Ratios (%), as of Mar 25, the value is 76.10. This value exceeds the healthy maximum of 70. It has increased from 41.68 (Mar 24) to 76.10, marking an increase of 34.42.
- For Price / BV (X), as of Mar 25, the value is 5.99. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.99, marking an increase of 2.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jagsonpal Pharmaceuticals Ltd:
- Net Profit Margin: 20.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.26% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 23.11% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 38.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.4 (Industry average Stock P/E: 42.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Innov8 3rd Floor, New Delhi Delhi 110020 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajpal Singh Kochhar | Chairman Emeritus |
| Mr. Harsha Raghavan | Chairman & Non-Exe.Director |
| Mr. Manish Gupta | Managing Director |
| Mr. Prithipal Singh Kochhar | Non Executive Director |
| Mr. Debasis Bikash Nandy | Independent Director |
| Ms. Radhika Madhukar Dudhat | Independent Director |
| Ms. Pallavi Dinodia Gupta | Independent Director |
FAQ
What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's intrinsic value (as of 07 February 2026) is ₹191.10 which is 13.75% higher the current market price of ₹168.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,125 Cr. market cap, FY2025-2026 high/low of ₹302/155, reserves of ₹240 Cr, and liabilities of ₹299 Cr.
What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?
The Market Cap of Jagsonpal Pharmaceuticals Ltd is 1,125 Cr..
What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 07 February 2026?
The current stock price of Jagsonpal Pharmaceuticals Ltd as on 07 February 2026 is ₹168.
What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is ₹302/155.
What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?
The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 26.4.
What is the Book Value of Jagsonpal Pharmaceuticals Ltd?
The Book Value of Jagsonpal Pharmaceuticals Ltd is 37.9.
What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?
The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 1.49 %.
What is the ROCE of Jagsonpal Pharmaceuticals Ltd?
The ROCE of Jagsonpal Pharmaceuticals Ltd is 23.0 %.
What is the ROE of Jagsonpal Pharmaceuticals Ltd?
The ROE of Jagsonpal Pharmaceuticals Ltd is 18.6 %.
What is the Face Value of Jagsonpal Pharmaceuticals Ltd?
The Face Value of Jagsonpal Pharmaceuticals Ltd is 2.00.